You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for VICTOZA


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for VICTOZA

Market Analysis and Price Projections for Victoza (Liraglutide)

Introduction to Victoza

Victoza, also known by its generic name liraglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and, under the brand name Saxenda, for weight loss. It is administered as a subcutaneous injection and has been a significant player in the diabetes and obesity treatment markets since its approval in 2010.

Current Market Scenario

Launch of Generic Victoza

In a significant development, Teva Pharmaceuticals has launched the first generic version of Victoza in the U.S., marking a major milestone in improving access to GLP-1 medications. This launch comes at a time when many patients with diabetes are facing shortages of other GLP-1 and incretin medications like Ozempic and Mounjaro[1].

Pricing of Generic Victoza

The generic version of Victoza is priced at $469.60 for a two-pack and $704.40 for a three-pack, representing a 16% to 17% reduction compared to the brand-name version, which typically costs around $560 for a two-pack and $850 for a three-pack[1].

Competition and Future Launches

In addition to Teva’s generic, two other companies, Sandoz and Viatris, are developing their own generic versions of Victoza. These could be launched as soon as December 2024, further increasing competition and potentially driving prices down[1].

Market Size and Growth Projections

Liraglutide Market Size

The liraglutide market, which includes both Victoza and Saxenda, is estimated to be worth $3.40 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 3.16% to reach $4 billion by 2029. North America is the largest and fastest-growing market for liraglutide[4].

Global GLP-1 Market

The global GLP-1 market is poised for significant growth, expected to reach $471.1 billion by 2032, with a CAGR of 33.2%. This growth is driven by increasing demand for GLP-1 medications in treating type 2 diabetes and obesity, particularly in North America[3].

Price Pressures and Market Dynamics

Impact of Generic Entries

The entry of generic versions of Victoza is expected to increase price competition in the GLP-1 market. As more generics become available, prices are likely to decline further, making these medications more accessible to a wider patient population[1].

Regulatory and Policy Influences

The Inflation Reduction Act, which includes provisions for Medicare price negotiations, is expected to add further pressure on GLP-1 pricing starting in 2027. This could lead to a 10% to 15% decline in prices as companies strive to maintain market share and secure insurance coverage[3].

Patient Access and Affordability

Cost Savings with Generics

The introduction of generic Victoza is anticipated to significantly improve patient access to GLP-1 medications. The reduced prices will help alleviate the financial burden on patients, especially those who are underinsured or uninsured. For instance, the generic version is already priced lower than the brand-name version, and additional generic entries are expected to drive prices down further[1].

Comparison with Other GLP-1 Medications

While Victoza offers modest A1C lowering and weight loss compared to newer GLP-1s like Ozempic, its generic availability makes it a more affordable option. For example, in the SUSTAIN 10 study, Victoza reduced A1C by 1% and led to a weight loss of about 4 pounds, whereas Ozempic reduced A1C by 1.7% and led to a weight loss of about 13 pounds[1].

Industry Segmentation and Major Players

Market Segmentation

The liraglutide market is segmented by brand (Victoza and Saxenda) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). North America is the largest market for both Victoza and Saxenda[4].

Major Players

Novo Nordisk, the original manufacturer of Victoza, has dominated the GLP-1 market for several years. However, with the entry of generics, other players like Teva, Sandoz, and Viatris are gaining traction. The competitive landscape is expected to evolve rapidly, with new entrants and generic versions challenging the market dominance of established brands[1][3].

Future Outlook

New Market Entrants and Innovations

By 2029, it is predicted that 16 new weight-loss drugs, including GLP-1s, could enter the market. This influx of new medications will further complicate market dynamics, potentially leading to lower prices and increased competition among manufacturers[3].

Regulatory and Policy Changes

The Inflation Reduction Act and other regulatory changes are expected to influence pricing and market access. Forced Medicare price negotiations for drugs like Wegovy starting in 2027 will add to the pricing pressure on GLP-1 medications[3].

Key Takeaways

  • Generic Availability: The launch of generic Victoza marks a significant step in improving access to GLP-1 medications, especially amid shortages of other GLP-1s.
  • Price Reduction: Generic versions are priced lower than the brand-name version, with further price declines expected as more generics enter the market.
  • Market Growth: The global GLP-1 market is projected to grow substantially, driven by increasing demand for type 2 diabetes and obesity treatments.
  • Competition: The entry of new generics and regulatory changes will increase competition, leading to potential price reductions and improved patient access.
  • Regulatory Impact: Policies like the Inflation Reduction Act will play a crucial role in shaping the pricing and accessibility of GLP-1 medications.

FAQs

Q: What is the current price of generic Victoza?

The generic version of Victoza is priced at $469.60 for a two-pack and $704.40 for a three-pack[1].

Q: When can we expect more generic versions of Victoza to be available?

Additional generic versions of Victoza are expected to launch as soon as December 2024[1].

Q: How does the efficacy of generic Victoza compare to newer GLP-1s?

Generic Victoza offers modest A1C lowering and weight loss compared to newer GLP-1s like Ozempic. For example, Victoza reduced A1C by 1% and led to a weight loss of about 4 pounds, whereas Ozempic reduced A1C by 1.7% and led to a weight loss of about 13 pounds[1].

Q: What is the projected growth of the global GLP-1 market?

The global GLP-1 market is expected to reach $471.1 billion by 2032, growing at a CAGR of 33.2%[3].

Q: How will regulatory changes impact the pricing of GLP-1 medications?

Regulatory changes, such as the Inflation Reduction Act, are expected to increase pricing pressure on GLP-1 medications, leading to potential price declines starting in 2027[3].

Sources

  1. diaTribe.org: "Generic Victoza Now Available in the U.S."
  2. SingleCare: "Victoza Coupons & Prices"
  3. PharmExec: "Obesity Drug Market Estimated to be Worth $200 Billion by 2031"
  4. Mordor Intelligence: "Liraglutide Market Size & Share Analysis - Industry Research Report"
  5. Drugs.com: "Victoza Prices, Coupons, Copay Cards & Patient Assistance"

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.